Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Tianjin
Clinical trial register · China

Clinical Trials in Tianjin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19224 matching records held by the registry are in this view. Synced 11 Nov 2026, 03:17 UTC
19224
Studies in scope
all four open statuses
11811
Recruiting now
open to new participants
2030
Lead sponsors
across recruiting studies
Top sites
Tianjin 28 Xingtai 5 Nanchang 3 Guangzhou 2 Kunming 2
Narrow the registerReset
Recruitment status
Phase
Site location
Tianjin28 Xingtai5 Nanchang3 Guangzhou2 Kunming2
All 8 locations
Target enrolment
to

Trials with a site in Tianjin

28 of 19224 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Tianjin Medical University Second Hospital
Phase 2
15
Tianjin
2027-08-31
Not yet open
Tianjin Medical University Second Hospital
Phase 2
150
Tianjin, Xingtai
2026-10-20
Recruiting
Tianjin Medical University Second Hospital
Not applicable
420
Tianjin
2026-10-01
Recruiting
Tianjin Medical University Second Hospital
Not applicable
670
Daqing, Nanchang, Tianjin
2026-08-10
Not yet open
Tianjin Medical University Second Hospital
Phase 2/3
114
Tianjin
2026-08-01
Recruiting
Tianjin Medical University Second Hospital
Phase 2
32
Tianjin
2026-08-01
Recruiting
Tianjin Medical University Second Hospital
Phase 2
120
Tianjin, Xingtai
2026-05-30
Recruiting
Tianjin Medical University Second Hospital
Phase 2
53
Tianjin, Xingtai
2026-03-16
Recruiting
Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma
NCT07441499Urothelial Carcinoma (UC), Bladder (Urothelial, Transitional Cell) Cancer, Liquid Biopsy
Tianjin Medical University Second Hospital
Observational
300
Tianjin
2026-03
Active, closed
Multimodal Prediction of Postoperative Prognosis After Partial Nephrectomy for Endophytic Renal Cell Carcinoma
NCT07697417Renal Cell Carcinoma, Kidney Neoplasms, Endophytic Renal Tumor, Postoperative Renal Function
Tianjin Medical University Second Hospital
Observational
406
Tianjin
2026-01-01
Recruiting
Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer
NCT07233252Renal Pelvic Carcinoma, Tislelizumab, PD-1 Inhibitor, Kidney-sparing
Tianjin Medical University Second Hospital
Phase 2
35
Tianjin
2025-11-25
Recruiting
Tianjin Medical University Second Hospital
Not applicable
144
Tianjin
2025-10-01
Recruiting
Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer
NCT07187635Bladder Cancer, Liquid Biopsy, Repeat Transurethral Resection of Bladder Tumor
Tianjin Medical University Second Hospital
Not applicable
350
Nanchang, Guangzhou, Xingtai, Kunming, Shanghai, Tianjin
2025-09-28
Recruiting
Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)
NCT07179783Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Castration-Resistant, Prostate Adenocarcinoma With Neuroendocrine Differentiation
Tianjin Medical University Second Hospital
Phase 2
28
Tianjin
2025-09-22
Active, closed
Tianjin Medical University Second Hospital
Not applicable
360
Xingtai, Guangzhou, Haerbin, Kunming, Nanchang, Tianjin
2025-09-20
Recruiting
Tianjin Medical University Second Hospital
Observational
60
Tianjin
2025-09-01
Recruiting
Tianjin Medical University Second Hospital
Not applicable
150
Tianjin
2025-09-01
Recruiting
Tianjin Medical University Second Hospital
Not applicable
220
Tianjin
2025-09-01
Recruiting
Tianjin Medical University Second Hospital
Phase 2
40
Tianjin
2025-07-31
Recruiting
Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC
NCT07126119Upper Tract Urothelial Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor, Nab-paclitaxel
Tianjin Medical University Second Hospital
Phase 2
35
Tianjin
2025-07-05
Recruiting
Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer
NCT07125547Ureteral Cancer, Neoadjuvant Therapy, PD-1 Inhibitor, Kidney-sparing
Tianjin Medical University Second Hospital
Phase 2
35
Tianjin
2025-07-05
Recruiting
Tianjin Medical University Second Hospital
Phase 1/2
65
Tianjin
2024-11-27
Recruiting
Tianjin Medical University Second Hospital
Phase 2
300
Tianjin
2024-11-01
Recruiting
Tianjin Medical University Second Hospital
Phase 1/2
72
Tianjin
2024-09-24
Recruiting
Tianjin Medical University Second Hospital
Observational
110
Tianjin
2024-04-01
Recruiting
Tianjin Medical University Second Hospital
Phase 2
21
Tianjin
2022-12-30
Active, closed
Tianjin Medical University Second Hospital
Phase 2
100
Tianjin
2022-10-10
Active, closed
Tianjin Medical University Second Hospital
Observational
190
Tianjin
2018-01-01
Rows per page Showing 1–28 of 28
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 November 2026. https://priyalifescience.com/clinical-trials-china/city/tianjin

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,224 studies in total at the last sync on 11 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 28 of those studies with a site in Tianjin that also match the filters currently applied.

How many clinical trials are recruiting in Tianjin?

22 of the 28 studies on this page are recruiting new participants as of the 11 Nov 2026, 03:17 UTC sync. A further 2 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Tianjin), 28 studies
PhaseStudiesRecruitingShare
Phase 2131146.4%
Not applicable7625%
Observational5317.9%
Phase 1/2227.1%
Phase 2/3103.6%

Most active sponsors

Lead sponsors with the most studies (Tianjin)
Lead sponsorStudiesRecruiting
Tianjin Medical University Second Hospital2822
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.